Compugen (CGEN)
(Delayed Data from NSDQ)
$1.90 USD
-0.01 (-0.52%)
Updated Apr 25, 2024 04:00 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CGEN 1.90 -0.01(-0.52%)
Will CGEN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CGEN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CGEN
Are You Looking for a Top Momentum Pick? Why Compugen (CGEN) is a Great Choice
BOX Gears Up to Report Q4 Earnings: Here's What to Expect
CGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Petrobras (PBR) Report Q4 Earnings Beat on Output Gains?
Is a Surprise Coming for Compugen (CGEN) This Earnings Season?
Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?
Other News for CGEN
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
Compugen initiated with bullish view at William Blair
Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
Compugen announces publication of peer reviewed paper on IL-18
Compugen to Participate in Two Upcoming Investor Conferences